367 related articles for article (PubMed ID: 27702624)
1. Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study.
Wykoff CC; Le RT; Khurana RN; Brown DM; Ou WC; Wang R; Clark WL; Boyer DS;
Am J Ophthalmol; 2017 Jan; 173():56-63. PubMed ID: 27702624
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
Heier JS; Korobelnik JF; Brown DM; Schmidt-Erfurth U; Do DV; Midena E; Boyer DS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Vitti R; Berliner AJ; Zeitz O; Metzig C; Holz FG
Ophthalmology; 2016 Nov; 123(11):2376-2385. PubMed ID: 27651226
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study.
Wykoff CC; Ou WC; Khurana RN; Brown DM; Lloyd Clark W; Boyer DS;
Br J Ophthalmol; 2018 May; 102(5):631-636. PubMed ID: 28814412
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
[TBL] [Abstract][Full Text] [Related]
5. Higher-Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal Fluid Index.
Ehlers JP; Uchida A; Hu M; Figueiredo N; Kaiser PK; Heier JS; Brown DM; Boyer DS; Do DV; Gibson A; Saroj N; Srivastava SK
Ophthalmol Retina; 2019 Dec; 3(12):1056-1066. PubMed ID: 31473172
[TBL] [Abstract][Full Text] [Related]
6. Baseline Factors Affecting Changes in Diabetic Retinopathy Severity Scale Score After Intravitreal Aflibercept or Laser for Diabetic Macular Edema: Post Hoc Analyses from VISTA and VIVID.
Dhoot DS; Baker K; Saroj N; Vitti R; Berliner AJ; Metzig C; Thompson D; Singh RP
Ophthalmology; 2018 Jan; 125(1):51-56. PubMed ID: 28764888
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
[TBL] [Abstract][Full Text] [Related]
8. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
Bahrami B; Hong T; Schlub TE; Chang AA
Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
[TBL] [Abstract][Full Text] [Related]
9. Outcomes in Patients with Diabetic Macular Edema Requiring Cataract Surgery in VISTA and VIVID Studies.
Moshfeghi AA; Thompson D; Berliner AJ; Saroj N
Ophthalmol Retina; 2020 May; 4(5):481-485. PubMed ID: 31924543
[TBL] [Abstract][Full Text] [Related]
10. EFFICACY AND SAFETY OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOCUSING ON PATIENTS WITH DIABETIC MACULAR EDEMA FROM JAPAN.
Terasaki H; Shiraki K; Ohji M; Metzig C; Schmelter T; Zeitz O; Sowade O; Kobayashi M; Vitti R; Berliner A; Shiraga F
Retina; 2019 May; 39(5):938-947. PubMed ID: 29470308
[TBL] [Abstract][Full Text] [Related]
11. Aflibercept with adjuvant micropulsed yellow laser versus aflibercept monotherapy in diabetic macular edema.
Khattab AM; Hagras SM; AbdElhamid A; Torky MA; Awad EA; Abdelhameed AG
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1373-1380. PubMed ID: 31127381
[TBL] [Abstract][Full Text] [Related]
12. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal aflibercept for diabetic macular edema.
Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM
Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal Panretinal Leakage and Ischemic Indices in Retinal Vascular Disease after Aflibercept Therapy: The PERMEATE Study.
Figueiredo N; Srivastava SK; Singh RP; Babiuch A; Sharma S; Rachitskaya A; Talcott K; Reese J; Hu M; Ehlers JP
Ophthalmol Retina; 2020 Feb; 4(2):154-163. PubMed ID: 31757691
[TBL] [Abstract][Full Text] [Related]
15. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study.
Barakat MR; Wykoff CC; Gonzalez V; Hu A; Marcus D; Zavaleta E; Ciulla TA
Ophthalmol Retina; 2021 Jan; 5(1):60-70. PubMed ID: 32829027
[TBL] [Abstract][Full Text] [Related]
16. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
Shah CP; Heier JS
Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
[TBL] [Abstract][Full Text] [Related]
17. One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema.
Schwarzer P; Ebneter A; Munk M; Wolf S; Zinkernagel MS
Ophthalmologica; 2019; 241(4):220-225. PubMed ID: 30654365
[TBL] [Abstract][Full Text] [Related]
18. Aflibercept and navigated versus conventional laser in diabetic macular oedema: a 12-month randomized clinical trial.
Blindbaek SL; Peto T; Grauslund J
Acta Ophthalmol; 2020 Jun; 98(4):347-352. PubMed ID: 31602811
[TBL] [Abstract][Full Text] [Related]
19. Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.
Laiginhas R; Silva MI; Rosas V; Penas S; Fernandes VA; Rocha-Sousa A; Carneiro Â; Falcão-Reis F; Falcão MS
Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):83-89. PubMed ID: 29082448
[TBL] [Abstract][Full Text] [Related]
20. Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema.
Sivaprasad S; Regnier SA; Fajnkuchen F; Wright J; Berger AR; Mitchell P; Larsen M
Adv Ther; 2016 Apr; 33(4):597-609. PubMed ID: 26951552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]